This fact sheet highlights PATH's work to develop a vaccine against respiratory syncytial virus (RSV) for use in a maternal immunization strategy in the developing world that can protect infants in the critical early months of life.
Corporate author(s): PATH
Publication date: September 2013
93 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- About PATH's work > Advancing technologies
- For advocates and policymakers > Child health
- Health technologies > Newborn health
- Vaccines and immunization > Miscellaneous
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA